Xyphos Biosciences
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 Kimball Way, South San Francisco, Ca...Phone Number
(650) 243-2951Website
www.xyphosinc.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Xyphos Biosciences
Xyphos is developing immuno-oncology therapeutics using flexible and controllable CAR-T cell therapy. The company is headquartered in San Francisco, California.Explore more
Xyphos Biosciences Org Chart
JR
Director, Pharmacology
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xyphos Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Xyphos Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Xyphos Biosciences recently announced quarterly report
Product Launch: Get notified when Xyphos Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at Xyphos Biosciences
Click to see if Xyphos Biosciences had a recent Job posting/layoffs
Check out if Xyphos Biosciences is spiking on competitors!
Xyphos Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Xyphos Biosciences has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Xyphos Biosciences
Compare insights from companies similar to Xyphos Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Xyphos Biosciences
<$5M
1-10
Private
-
-
KS
Ksenya ShchorsSenior Director, Scientific Strategy, Cell Therapy & Immuno-Oncology
Company Profile Activity
Activity Insights
Xyphos Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Xyphos Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Xyphos Biosciences.
Xyphos Biosciences Tech Stack
A closer look at the technologies used by Xyphos Biosciences
See more technologies
Xyphos Biosciences News & Media
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas). For this collaboration, Phenomic and Astellas will explore the ability of antibodies, developed by Phenomic and directed at a novel target of thePHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
SAN DIEGO, March 6, 2023 /PRNewswire/ -- Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company. The...Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology
- Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass., June 1, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and GO Therapeutics, Inc. (Co-Founder and CEO: Constantine Theodoropulos, "GO")...United Immunity and Xyphos, an Astellas Company, to Collaborate on Next Generation Nano-Immunotherapies for Cancer Treatment
TOKYO, Jan. 15, 2021 /PRNewswire/ -- United Immunity, Co., Ltd. (CEO, Naozumi Harada, Ph.D. Mie, Japan), a drug discovery biotech specializing in nanoparticle-based cancer immunotherapies (nano-immunotherapies), has entered into a joint research agreement as of December 2020 with Xyphos Biosciences, Inc., (California, US), a subsidiary of Astellas Pharma Inc. (Tokyo, Japan). United Immunity logo. United Immunity was established to commercialize the results of longstanding collaboration between t
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xyphos Biosciences
Sign Up For FreeTo access detailed company insights
Xyphos is developing immuno-oncology therapeutics using flexible and controllable CAR-T cell therapy. The company is headquartered in San Francisco, California.... Read More
